CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病的 CAR 细胞治疗：当前格局与未来方向
英文原题：CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.
查看英文原题
CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法革新了B细胞恶性肿瘤的治疗，但这一成功尚未在急性髓系白血病（AML）中重现。AML细胞上的许多抗原也存在于健康造血祖细胞中，因此CAR-T 治疗可能引发难以接受的毒性。此外，AML克隆演化、抗原逃逸及肿瘤微环境（TME）的影响也可能妨碍治疗效果。近年来，研究者尝试了多种创新方法克服这些障碍，包括联合靶向及新抗原靶向、逻辑门控CAR、通过CAR-T 装甲化抵消TME影响，以及在CAR-T 治疗后进行工程化抗原阴性干细胞移植巩固。尽管如此，目前尚无CAR-T 疗法获批用于AML。部分早期试验数据具有前景，但CAR-T 是否能成为治疗AML的可行策略仍有待确定。
展开英文摘要原文
Chimeric antigen T cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, but has not seen this success replicated in acute myeloid leukemia (AML). Many antigens present on AML cells are shared with healthy hematopoietic progenitors, posing a risk of prohibitive toxicity with CAR-T therapy.
Furthermore, clonal evolution of AML, antigen escape and effects of tumor microenvironment (TME) may hinder the efficacy of treatment. A number of innovative approaches to overcome these barriers have been attempted in recent years, including combinatorial and neoantigen targeting, logic-gated CARs, CAR-T armoring to overcome the effects of TME and CAR-T consolidation of engineered antigen-negative stem cell transplants.
Despite this, no CAR-T treatments are currently licensed for AML. While some early trial data seems promising, it remains to be seen whether CAR-T therapy is a viable strategy for treatment of AML.
论文信息
- 作者
- Hederih J、Patrick J、Gannon I、Rampotas A、Roddie C、Sellar R
- 单位
- Department of Haematology, University College London Cancer Institute, University College London, London, UK.United Kingdom
- 文献类型
- 综述
- 期刊
- Immunotherapy2026 May
- 原文标识
- PubMed 42319045 · DOI 10.1080/1750743X.2026.2689849